Press Releases

 
Press Releases
  Date Title and Summary View
Mar 28, 2017
HERTFORDSHIRE, England and PITTSBURGH, March 28, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the appointment of Daniel M. Gallagher as chief legal officer. He will be joining the company on April 17, 2017. Gallagher joins Mylan from Patomak Global Partners, a consulting firm...
Mar 20, 2017
HERTFORDSHIRE, England and PITTSBURGH, March 20, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), a leading global pharmaceutical company, today announced receipt of tentative approval from the U.S. Food and Drug Administration under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application for Efavirenz, Lamivud...
Mar 13, 2017
HERTFORDSHIRE, England and PITTSBURGH, March 13, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Exemestane Tablets, 25 mg, a generic version of the reference listed drug, Pfizer's Aromasin® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Dr...
Mar 13, 2017
HERTFORDSHIRE, England and PITTSBURGH, March 13, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that Mylan has agreed to the terms of a global settlement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. in relation to patents for Herceptin® (trastuzumab), which provides Mylan with global licenses for its trastuzumab prod...
Mar 10, 2017
HERTFORDSHIRE, England and PITTSBURGH, March 10, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that the company will present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2017, in Miami. The presentation is scheduled to begin at 9:30 a.m. ET. Interested p...
Mar 10, 2017
HERTFORDSHIRE, England and PITTSBURGH, March 10, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), today announced the U.S. launch of Desvenlafaxine Extended-release Tablets, 50 mg and 100 mg, a generic version of Pfizer's Pristiq® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated Ne...
Mar 1, 2017
HERTFORDSHIRE, England and PITTSBURGH, March 1, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced its financial results for the quarter and year ended December 31, 2016 and provided 2017 guidance. Fourth Quarter 2016 Financial Highlights Total revenues of $3.27 billion, up 31% compared to the prior year peri...
Feb 16, 2017
HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Feb. 16, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration (FDA) has accepted Mylan's Biologics License Application (BLA) for MYL-1401H, a proposed biosimilar to Neulasta®  (pegfi...
Feb 14, 2017
HERTFORDSHIRE, England and PITTSBURGH, Feb. 14, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today applauds the rebranding of the Generic Pharmaceutical Association (GPhA) to the Association for Accessible Medicines (AAM). Mylan CEO Heather Bresch commented, "The launch of GPhA's new brand - the Association for Accessible Medicin...
Feb 3, 2017
HERTFORDSHIRE, England and PITTSBURGH, Feb. 3, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will host an Investor Day on March 1, 2017 in New York City. Mylan CEO Heather Bresch and the company's senior leadership team will present the company's financial guidance for 2017 and an overview of the company's strategic vi...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase